Press Releases
  Date Title and Summary View
Sep 22, 2015
ROCKVILLE, Md., Sept. 22, 2015 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious diseases, today announced that Scott Koenig, M.D., Ph.D....
Sep 3, 2015
ROCKVILLE, Md., Sept. 03, 2015 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq:MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious diseases, today announced that its senior management w...
Aug 5, 2015
-- Fourth bi-specific DART® molecule, MGD011, in clinical testing         -- Margetuximab Phase 3 SOPHIA metastatic breast cancer study initiated        -- Balance sheet strengthened with completion of $141 million equity offering ROCKVILLE, Md., Aug. 05, 2015 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ:MGNX), a clinical-stage biop...
Aug 4, 2015
Rockville, MD, Aug. 04, 2015 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious diseases, today announced that Scott Koenig, M.D., Ph.D., ...
Jul 29, 2015
ROCKVILLE, Md, July 29, 2015 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX) today announced that on Wednesday, August 5, 2015, the Company will release its financial results for the quarter ended June 30, 2015. The Company's management team will host a conference call discussing the Company's financial results and recent corporate developme...
Jul 28, 2015
— Triggers $10 million milestone payment from Janssen  — Fourth DART® molecule to enter the clinic in last 12 months ROCKVILLE, Md., July 28, 2015 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq:MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therape...
Jul 14, 2015
ROCKVILLE, Md., July 14, 2015 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq:MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious diseases, announced the pricing of an underwritten public of...
Jul 13, 2015
ROCKVILLE, Md., July 13, 2015 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq:MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious diseases, announced that it has commenced an underwritten pu...
May 30, 2015
ROCKVILLE, Md., May 30, 2015 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq:MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious diseases, announced that updated results of the Phase 1 study...
May 27, 2015
—    MGD006 Enables T Cells to Recognize and Kill Leukemia Cells —     Research Paved the Way for Human Clinical Trials ROCKVILLE, Md., May 27, 2015 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based t...
May 13, 2015
ROCKVILLE, Md., May 13, 2015 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq:MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious diseases, today announced that clinical data from its Phase 1...
May 6, 2015
-- Company's third bi-specific DART® molecule, MGD010, in clinical testing -- FDA clears IND for fourth DART, MGD011 - Janssen to initiate clinical testing -- Margetuximab Phase 3 SOPHIA study in metastatic breast cancer to initiate 3Q 2015 ROCKVILLE, Md., May 6, 2015 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq:MGNX),...
Apr 29, 2015
ROCKVILLE, Md., April 29, 2015 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq:MGNX) today announced that on Wednesday, May 6, 2015, the Company will release its financial results for the quarter ended March 31, 2015. The Company's management team will host a conference call discussing the Company's financial results and recent corporate developments...
Apr 28, 2015
ROCKVILLE, Md., April 28, 2015 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq:MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious diseases, today announced that Scott Koenig, M.D., Ph.D., P...
Apr 20, 2015
ROCKVILLE, Md., April 20, 2015 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq:MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious diseases, today announced the presentation of pre-clinical ...
Apr 16, 2015
ROCKVILLE, Md., April 16, 2015 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq:MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious diseases, today announced that pre-clinical data from progr...
Apr 7, 2015
Rockville, MD, April 7, 2015 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious diseases, today announced that Scott Koenig, M.D...
Mar 16, 2015
ROCKVILLE, Md., March 16, 2015 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious diseases, today announced the initiation of a ...
Mar 3, 2015
-- Four oncology molecules in clinical development, including two bi-specific DART® molecules -- Margetuximab Phase 3 SOPHIA study in metastatic breast cancer to initiate 3Q 2015 -- Cash runway extends into 2018 ROCKVILLE, Md., March 3, 2015 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq:MGNX), a clinical-stage biopharmaceutic...
Mar 2, 2015
MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious diseases, today announced that Scott Koenig, M.D., Ph.D., President and CEO will present at th...
Feb 24, 2015
MacroGenics, Inc. (Nasdaq: MGNX) today announced that on Tuesday, March 3, 2015, the Company will release its financial results for the fourth quarter and full year 2014. The Company's management team will host a conference call discussing the Company's financial results and recent corporate developments on Tuesday, March 3, 2015 at ...
Feb 5, 2015
MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious diseases, today announced that Scott Koenig, M.D., Ph.D., President and CEO will present at th...
Jan 27, 2015
MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer and autoimmune diseases, today announced the closing of the global collaboration and license agreement for MGD011 with Janssen Biotech, Inc. T...
Jan 12, 2015
MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as various autoimmune disorders and infectious diseases, today announced that Scott Koenig, M.D., Ph.D., President and CEO will prese...
Dec 22, 2014
MacroGenics licenses MGD011 (CD19 x CD3 DART®) to Janssen $50 million upfront license fee paid to MacroGenics, and a $75 million equity investment by Johnson & Johnson Innovation - JJDC, Inc. MacroGenics may elect to fund a portion of late-stage development costs in exchange for a U.S. and Canada profit share MacroGenic...
Page: FirstPrevious
3
... NextLast
= add release to Briefcase

Please note – you will leave a website owned by MacroGenics, Inc.

MacroGenics is not responsible for any content on the third party website.

Ok Close